



**Loop**  
CamAPS | FX

# Enjoy freedom of choice.



**mylife Loop  
now on iOS**



**Discreetness and convenience.  
With the app-controlled mylife YpsoPump.**



More freedom. More confidence. With mylife.



## Supporting children and families

The mylife Loop system is suitable for use in children aged 2 years and over, and is set up using key details such as total daily insulin dose, weight, and carbohydrate ratios. Once started, the system automatically adjusts insulin delivery based on CGM sensor readings to help maintain glucose levels within the target range, helping support everyday diabetes management for children and their families.

Image for illustration purposes only.



## Our path into the future of personalised diabetes therapy

Ypsomed, with its headquarters and multiple production sites based in Switzerland, Germany and others, offers its product portfolio of devices for people with diabetes under the brand of mylife Diabetescare.

The name Ypsomed is a combination of “ipso”, which means “self”, and “med”, which stands for medication. The company name illustrates our core business: to develop, manufacture and market innovative, high-quality and reliable products and services which allow you to administer your medication in a simple way.

The choices you make on a daily basis have bigger consequences for you than they would for most people. Managing these decisions is a huge achievement. That is why at Ypsomed, we work hard to help you make those choices and help you be ready for whatever comes.

We are creating the path to a sustainable future: we take responsibility for the ecological, social and societal impact of our actions and are committed to long-term and sustainable development. Sustainability has been firmly established in our corporate strategy. Not only do we want to make life easier for people with diabetes, we also want to do so in a way which conserves the environment and limits our footprint.

**Our mission:  
making life with diabetes easier.**



## Put your glucose management on Auto mode

### mylife Loop: the automated insulin delivery system that runs from your smartphone


Smartphone based therapy management is the future of diabetes treatment. Combine the mylife YpsoPump insulin pump, the mylife CamAPS FX mobile application and the Dexcom G6 or FreeStyle Libre 3 Plus Continuous Glucose Monitoring (CGM) sensor for an automated insulin delivery system managed directly from your smartphone. The integration of automated insulin delivery into the mylife YpsoPump system portfolio allows you time away from your diabetes and more freedom to do what you love doing.



### Automated adjustment of insulin delivery based on sensor readings from your CGM system to help maintain glucose levels within the target range

- mylife CamAPS FX is the only automated insulin delivery algorithm intended for use in ages one year and over\*
- mylife CamAPS FX is intended for use in pregnancy
- For increased privacy and convenience, you are able to deliver a meal bolus directly from your smartphone
- Parents and caregivers can have peace of mind thanks to remote monitoring<sup>1</sup>
- Improved quality of life thanks to an adaptive and self-learning algorithm<sup>2</sup>
- Flexibility with “Boost” and “Ease-off” modes
- Personalised diabetes management with customisable personal glucose target

\*Intended for use in people with type 1 diabetes aged two years and over when used in combination with Dexcom G6 or FreeStyle Libre 3 Plus.



## Supporting you through preconception and pregnancy

The mylife Loop system can be used by people planning a pregnancy. The system is set up using key details such as insulin doses, weight, and carbohydrate ratios, and then automatically adjusts insulin delivery to support everyday diabetes management during preconception and pregnancy.

Illustrative example only. Individual experiences may vary.

**The only automated insulin delivery algorithm intended for use in ages one year and over\***

There is an overall acceptance of the closed-loop approach across all age groups: very young children<sup>3</sup>, children<sup>2,4,5</sup>, adolescents<sup>2,4,5</sup>, adults<sup>2,4,6</sup> and older adults<sup>7</sup>. The use of CamAPS FX in young children aged 1 to 7 years documented clinically and statistically significant reduction of HbA1c by 0.4 %, and an increase in time in target glucose range by 9% without increasing time in hypoglycaemia below 3.9mmol/L<sup>3</sup>. The comparator was sensor augmented pump therapy applying identical insulin pump and identical glucose sensor but not using the control algorithm. An extension phase of the study confirmed the long-term efficacy of CamAPS FX over a period of 18 months.<sup>8</sup>



**Parents and caregivers can have peace of mind thanks to remote monitoring**

Control and monitoring of glucose, especially overnight, is a relief and leads to a better night's sleep. The burden of diabetes for parents and caregivers is reduced significantly and they feel less worried about their child's glucose management.<sup>1</sup>



**Improved glucose management during pregnancy**

Women strive to achieve tight glycaemic management during pregnancy to reduce the risks of obstetric and neonatal complications.<sup>9,10</sup> Thanks to its unique technology and highly adaptive capabilities, CamAPS FX demonstrated in the AiDAPT (Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes) study that it can support women achieving their treatment goals during pregnancy, providing 10.5 % additional time in the pregnancy specific range, over the entire pregnancy period, without increasing hypoglycaemias.<sup>11</sup> Furthermore, women using closed-loop report a more enjoyable pregnancy experience.<sup>12</sup>

\*Intended for use in people with type 1 diabetes aged two years and over when used in combination with Dexcom G6 or FreeStyle Libre 3 Plus.

**Improved quality of life thanks to an adaptive and self-learning automated insulin delivery system<sup>2</sup>**

The mylife CamAPS FX app constantly learns and quickly adapts to ever changing insulin needs. It adjusts to diurnal and day-to-day variations in insulin requirements and compensates for over and under-dosing of meal bolus. The algorithm adjusts insulin delivery accordingly to adjust to ever-changing glucose levels. This enables efficient use in all life circumstances<sup>2</sup>.

**Personalised and flexible diabetes management**

The personal glucose target can be adjusted between 4.4–11.0 mmol/L (80–198 mg/dL) in 30 minute segments. Furthermore, with the slowly absorbed meal function the algorithm will deliver insulin over a prolonged duration, depending on glucose levels. The “Ease-off” mode reduces insulin delivery depending on glucose levels, raises the glucose target temporarily and stops insulin delivery if the glucose level is predicted to fall below target. On the flip side, the “Boost” mode makes the algorithm more responsive and increases insulin delivery.





## Supporting everyday activities and exercise

The mylife Loop system helps manage insulin delivery throughout daily life, including during physical activity. By automatically adjusting insulin based on glucose data, it is designed to support users in maintaining their individual diabetes management routine with confidence.

Illustrative example only. Individual experiences may vary.

### Hybrid closed-loop with the mylife CamAPS FX app: features and benefits

#### Automated insulin delivery with mylife Loop

- Intended for use in people with type 1 diabetes aged two years and over when used in combination with Dexcom G6 or FreeStyle Libre 3 Plus sensor
- Intended for use in pregnant women with type 1 diabetes
- Discreet automated insulin delivery on the mylife YpsoPump from your smartphone
- Automated adjustment of insulin delivery based on sensor readings from your CGM system to help maintain glucose levels within the target range
- Personalised diabetes therapy management with freely adjustable glucose targets
- Automated insulin delivery system, which learns and adjusts according to your needs
- Option to use the “Boost” mode when more insulin is required or the “Ease-off” mode when less insulin is required
- Only a few settings needed to set-up the app: weight, total daily dose and bolus calculator settings
- For minimum operating system requirements of the mylife CamAPS FX app please see <https://camdiab.com/faq>

#### Remote bolus delivery

- Discreet and convenient remote bolus delivery from your smartphone on the mylife YpsoPump
- Bolus delivery for standard bolus type (meal bolus) with use of the app-based bolus suggestion calculator

#### CGM integration

- Android and iOS smartphones compatible with Dexcom G6\*
- Android and iOS smartphones compatible with FreeStyle Libre 3 Plus CGM sensors\*\*
- Direct use of CGM values for convenient bolus suggestion calculation
- Display of current sensor reading, glucose trend and of historical CGM values
- CGM alerts in case of high or low glucose levels
- Setting up of sensor and transmitter within the app

#### Remote monitoring

- Companion remote monitoring: the mylife CamAPS FX app allows user’s data to be shared with up to 10 “companions”. Companion remote monitoring mirrors the data from the user’s mylife CamAPS FX app.
- SMS based remote monitoring: the mylife CamAPS FX app supports SMS based remote monitoring. All app generated alarms and alerts will be sent via SMS message to up to 5 “followers”. On iOS, no SMS “Follower” function is available.

#### Data sharing

- mylife CamAPS FX app on smartphone: generation and export of PDF reports including glucose statistics, insulin statistics, Auto mode and alert statistics, information about settings and weekly overviews.
- mylife Cloud: automated data upload from the mylife CamAPS FX app to the mylife Cloud for use with healthcare professionals.
- Glooko® automated data upload from the mylife CamAPS FX app to the Glooko® platform to share data with healthcare professionals.

\* If using Dexcom G6 CGM system check compatibility list here: <https://www.dexcom.com/compatibility/g6>

\*\* If using FreeStyle Libre 3 Plus sensor check compatibility list in the “Mobile Device & OS Compatibility” guide here: <http://www.diabetescare.abbott/support/manuals.html>

Visit our website for detailed information about mylife Loop:  
[www.pharmacodiabetes.co.nz/mylife-insulin-pump/mylife-loop/](http://www.pharmacodiabetes.co.nz/mylife-insulin-pump/mylife-loop/)



## Supporting diabetes management at every stage of life

Starting on mylife Loop has been a great choice for people looking for a simple and supportive way to manage their diabetes.

Illustrative example only. Individual experiences may vary.



## mylife Cloud – therapy management made easy

The therapy management is an easy-to-use and easy-to-share solution for diabetes therapy data.

- Ability to upload therapy data and therapy settings from the mylife CamAPS FX app
  - mylife YpsoPump and bolus calculator settings overview
  - Variety of reports and statistics to assist in the therapy evaluation
  - Optional data sharing between the user and the healthcare professional for simplified therapy management and remote therapy support
- All relevant therapy data in one place for a secure backup storage

There are different ways to share your diabetes data with your clinic, including systems like Glooko. Please check with your clinic to see which system they use.



\* Country-dependent availability. Available therapy data in third-party platforms dependent on each individual implementation

**Our aim is to optimise communication and data transfer between you and your healthcare professional.**



## mylife YpsoPump – the intuitive<sup>13</sup> and discreet insulin pump

- Simple menu navigation through self-explanatory icons<sup>13</sup>
- The icon-based menu allows for intuitive operation<sup>13</sup> via touchscreen
- Every function is just a few swipes away
- Small and lightweight (weighs only 83 grams)



### Carrying systems for your mylife YpsoPump

Our broad selection of carrying systems allows you to wear your mylife YpsoPump comfortably and discreetly. Whether you want a silicone cover, bra or rotation clip, neck or waist pouch or pouches designed for kids – find the right carrying system online<sup>14</sup>:

[www.pharmacodiabetes.co.nz/mylife-insulin-pumps/mylife-consumables/](http://www.pharmacodiabetes.co.nz/mylife-insulin-pumps/mylife-consumables/)



Experience the mylife YpsoPump in 3D  
with the YpsoPump Explorer app.





## Cartridge – flexibility with insulin of choice

- Self-filled mylife YpsoPump Reservoir with rapid-acting insulin of choice (160U/1.6 ml)
- Easy-to-handle filling system
- No minimum filling quantity required and easy-to-read filling level
- The reservoir can be filled in advance and stored in the fridge for up to 30 days




## Infusion set – more freedom of movement

- Rotating connection of the mylife YpsoPump Orbit infusion set for easy and highly flexible site selection<sup>13</sup>
- Tan and semi-transparent tape for improved discreetness
- No requirement to replace the infusion set with every new insulin cartridge for more flexibility<sup>13</sup>
- Quick and easy insertion of the Orbit infusion set with the small, lightweight and reusable mylife Orbit inserter
- YpsoPump Inset offers an all-in-one infusion set with soft cannula



mylife Orbit infusion sets are available in the following options:

- Orbit Micro: Steel cannula
- Orbit Soft: Teflon (soft) cannula



YpsoPump Inset infusion sets are available with a soft cannula.



## Information security

The digital world influences a large part of our lives and has become indispensable. The security of networked systems in this virtual world is of paramount importance, and as a manufacturer of these devices, Ypsomed is aware of the danger of cyber-attacks and strives to be prepared for all risks.

**When it comes to security, we make no compromises.**

We have understood, through our many years of experience, what we need to focus on in order to ensure the highest level of security for our users. When it comes to patient safety, cyber security and customer convenience, Ypsomed makes no compromises and offers state-of-the-art security and secure interoperability. More information: [www.mylife-diabetescare.com/information-security](http://www.mylife-diabetescare.com/information-security)




## Are you interested in learning more about our modular system?

**Your opinion matters. Your questions, too.**

To learn more about our products and solutions, contact our customer service team on 0800 45 82 67.

**Visit our website for detailed  
information about our products:  
[www.pharmacodiabetes.co.nz](http://www.pharmacodiabetes.co.nz)**



**Your needs are close to our hearts  
and what motivates us.  
That is why our customer service is  
available 24/7 for your questions  
or suggestions.**

1. Musolino G. et al.: Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes. *PediatrDiabetes*. 2019 Sep;20(6):794-799. DOI: 10.1111/peidi.12872
2. Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. *J Diabetes Sci Technol*. 2017 Nov;11(6):1080-1088. DOI: 10.1177/1932296817702656
3. Ware J. et al.: Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. *N Engl J Med*. 2022 Jan;386(3):209-219. DOI: 10.1056/NEJMoa2111673
4. Tauschmann M. et al.: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. *Lancet*. 2018 Oct;392(10155):1321-1329. DOI: 10.1016/S0140-6736(18)31947-0
5. Ware J. et al.: Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. *The Lancet Digital Health*. 2022 Apr;4(4):e245-e255. DOI:10.1016/S2559-7500(22)00020-6
6. Boughton C. K. et al. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study. *Diabetes Obes Metab*. 2021; 23(6):1389-1396. DOI: 10.1111/dom.14355
7. Boughton C.K. et al.: Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. *Lancet Healthy Longev*. 2022; 3(3):e135-e142. DOI: 10.1016/S2666-7568(22)00005-8
8. Ware J, et al. Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial. *Diabetes Care*. 2024 Dec 1;47(12):2189-2195. doi: 10.2337/dc24-1313
9. Diabetes in pregnancy: management from preconception to the postnatal period. NICE guideline [NG3]. Published: 25 Feb 2015. Last updated: 16 Dec 2020. <https://www.nice.org.uk/guidance/ng3/chapter/recommendations>
10. National Pregnancy in Diabetes (NPID) Audit Report 2020, England and Wales, 01 Jan 2019 to 31 Dec 2020; published on 14 Oct 2021: <https://digital.nhs.uk/data-and-information/publications/statistical/national-pregnancy-in-diabetes-audit/2019-and-2020>
11. Lee TTM et al.: Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes. *N Engl J Med*. 2023 Oct 26;389(17):1566-1578. doi: 10.1056/NEJMoa2303911. Epub 2023 Oct 5. PMID: 37796241
12. Lawton J et al.: Listening to Women: Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy. *Diabetes Technol Ther*. 2023 Dec;25(12):845-855. doi: 10.1089/dia. 2023.0323. Epub 2023 Nov 7. PMID: 37795883; PMCID: PMC10698780
13. Waldenmaier D. et al.: First User Experiences With a Novel Touchscreen-Based Insulin Pump System in Daily Life of Patients With Type 1 Diabetes Experienced in Insulin Pump Therapy. *Journal of Diabetes Science and Technology*. 2019;13(1):96-102. DOI: 10.1177/1932296818785386.
14. Product availability of the carrying systems without guarantee. The range of carrying systems is constantly being adapted. The currently available products are on the website: [www.mylife-diabetescare.com/carrying-systems](http://www.mylife-diabetescare.com/carrying-systems)

**Disclaimer:** The product images are for illustrative purposes only. // mylife, YpsoPump and Orbit are registered trademarks of Ypsomed AG. // CamAPS is a registered trademark of CamDiab Ltd. // Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries. // The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. // The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ypsomed is under license. // iPhone and Apple are trademarks of Apple Inc., registered in the US and other countries and regions. // Other trademarks and trade names are those of their respective owners.

For safety information on mentioned products, see Instructions for Use or <https://pharmacodiabetes.co.nz/our-products/insulin-pumps/mylife-ypsopump/mylife-ypsopump/>



Diabetescare

# Freedom and confidence. With mylife.



Infusion systems



Infusion set



Therapy  
management



Reservoir/  
Cartridge

Pharmaco (N.Z.) Ltd // 4 Fisher Crescent, Mt Wellington // Auckland 1060 //  
support@pharmacodiabetes.co.nz // www.PharmacoDiabetes.co.nz //  
Customer Care: 0800 GLUCOSE (0800 45 82 67)

ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE. Ask your health professional if this product is right for you. mylife YpsoPump is intended for subcutaneous insulin delivery in diabetes mellitus therapy. Only rapid-acting insulin at a concentration of 100 U/mL (insulin analogue) may be used with the mylife YpsoPump system.

Pharmaco (NZ) Ltd, Auckland.  
File No. 0226YP01  
TAPS NP24207

**Disclaimer:** The information shared in this brochure reflect individual experiences with the mylife Loop system. These are for educational purposes only and do not constitute medical advice. Consult your healthcare professional for medical advice.